Cartalax 20mg

Cartalax is a tetrapeptide (Ala-Glu-Asp-Gly) from the Khavinson series targeting cartilaginous tissue — joints, intervertebral discs, and chondrocyte biology. Cartilage is avascular and has extremely limited regenerative capacity in adults: chondrocytes maintain the extracellular matrix through a balance of synthesis and degradation that shifts unfavorably with age. Matrix metalloprotease activity increases, anabolic signaling declines, and the tissue deteriorates. Unlike most tissues, there's no significant cell renewal to offset that loss. This is the biological problem Cartalax research addresses.

The Khavinson mechanism applied to cartilage: short peptides can reach chondrocyte nuclei and influence the transcriptional programs governing matrix synthesis and turnover. Published Khavinson data examines gene expression changes in chondrocytes, collagen and proteoglycan synthesis rates, and effects in age-related cartilage degeneration models. The data is primarily in vitro and in some Russian-language publications, though English-language work exists in gerontology and peptide biology journals. Note that Cartalax shares its sequence (Ala-Glu-Asp-Gly) with Cortagen — the same sequence, different tissue target, consistent with the Khavinson tissue-distribution hypothesis.

Specifications

Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.

Quality: HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.

For research purposes only. Not for human consumption.